Literature DB >> 14698571

Vesicular systems in ocular drug delivery: an overview.

Indu P Kaur1, Alka Garg, Anil K Singla, Deepika Aggarwal.   

Abstract

The main aim of pharmacotherapeutics is the attainment of effective drug concentration at the intended site of action for a sufficient period of time to elicit a response. Poor bioavailability of drugs from ocular dosage form is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. Though the topical and localized application are still an acceptable and preferred way to achieve therapeutic level of drugs used to treat ocular disorders but the primitive ophthalmic solution, suspension, and ointment dosage form are no longer sufficient to combat various ocular diseases. This article reviews the constraints with conventional ocular therapy and explores various novel approaches, in general, to improve ocular bioavailability of the drugs, advantages of vesicular approach over these and the future challenges to render the vesicular system more effective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14698571     DOI: 10.1016/j.ijpharm.2003.09.016

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  52 in total

1.  Diffusion Regulation in the Vitreous Humor.

Authors:  Benjamin Tillmann Käsdorf; Fabienna Arends; Oliver Lieleg
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

2.  Impacts of nanomedicines in ocular pharmacotherapy.

Authors:  Ailar Nakhlband; Jaleh Barar
Journal:  Bioimpacts       Date:  2011-06-09

3.  Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.

Authors:  Sabyasachi Maiti; Sayon Paul; Ranjit Mondol; Somasree Ray; Biswanath Sa
Journal:  AAPS PharmSciTech       Date:  2011-06-14       Impact factor: 3.246

4.  Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system.

Authors:  Indu Pal Kaur; Deepika Aggarwal; Harinder Singh; Shilpa Kakkar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

Review 5.  Recent patents on ophthalmic nanoformulations and therapeutic implications.

Authors:  Ann-Marie Ako-Adounvo; Ramesh C Nagarwal; Lais Oliveira; Sai H S Boddu; Xiang S Wang; Surajit Dey; Pradeep K Karla
Journal:  Recent Pat Drug Deliv Formul       Date:  2014

6.  NC-1059: a channel-forming peptide that modulates drug delivery across in vitro corneal epithelium.

Authors:  Jesica Martin; Pradeep Malreddy; Takeo Iwamoto; Lisa C Freeman; Harriet J Davidson; John M Tomich; Bruce D Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

7.  Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments.

Authors:  Jie Liang Phua; Aihua Hou; Yuan Siang Lui; Tanima Bose; George Kanianthara Chandy; Louis Tong; Subbu Venkatraman; Yingying Huang
Journal:  Int J Mol Sci       Date:  2018-09-29       Impact factor: 5.923

8.  Niosome-encapsulated gentamicin for ophthalmic controlled delivery.

Authors:  Ghada Abdelbary; Nashwa El-Gendy
Journal:  AAPS PharmSciTech       Date:  2008-06-18       Impact factor: 3.246

9.  Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin.

Authors:  Khaled Mohamed Hosny
Journal:  AAPS PharmSciTech       Date:  2009-11-10       Impact factor: 3.246

Review 10.  Approaches for enhancing oral bioavailability of peptides and proteins.

Authors:  Jwala Renukuntla; Aswani Dutt Vadlapudi; Ashaben Patel; Sai H S Boddu; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-02-18       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.